Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer.

Droplet digital PCR measurements of circulating tumor (ct)DNA to assess minimal residual disease before the initiation of ...

Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify ...

The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) as a second-line treatment option for BRAF V600E mutated mCRC after an ...

Colon cancer is the disease characterized by the development of malignant cells in the lining or epithelium of the first and longest portion of the large intestine. Wnt5a is a member of the Wnt ...

has been given accelerated approval by the FDA as first-line therapy for BRAF V600E-mutated metastatic colorectal cancer, one of a series of new cancer indications that the company reckons will ...

Medscape Medical News, April 16, 2025 Blood Test Predicts Melanoma Recurrence Researchers used digital polymerase chain reaction assays to measure BRAF V600E or BRAF V600K circulating tumor DNA in ...

Recently, an oncogenic V600E hotspot mutation within BRAF, a kinase encoding gene from the RAS/RAF/MAPK pathway, has been found to be associated with sporadic MSI-H colon cancer, but its association ...